| Biomarker ID | 1290 |
| PMID | 24394557 |
| Year | 2014 |
| Biomarker | VGLL3 |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: 1.09 (95% CI: 1.04–1.15) |
| Effect on Pathways | Pathways include: FZD6 knockdown 96h A549, STK3 knockdown 96h HA1E, GRK5 knockdown 96h A549, PRKD2 knockdown 96h HA1E, P2RX4 knockdown 96h A549 |
| Experiment | Overall Survival Vs No Survival |
| Type of Biomarker | Prognostic |
| Cohort | 189 patients from Swedish Cohort were selected for analysis. Survival information was available for 185 patients. 22 are alive, 98 died due to prostate cancer and 65 died due to other causes. 152 samples were available for the analysis of this gene |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.0001 |
| Method Used | NA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | VGLL3 |